| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stéphane Pédeboscq, Denis Gravier, Françoise Casadebaig, Geneviève Hou, Arnaud Gissot, Christophe Rey, François Ichas, Francesca De Giorgi, Lydia Lartigue, Jean-Paul Pometa. Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines. Bioorganic & medicinal chemistry. vol 20. issue 22. 2013-03-19. PMID:23063521. |
we evaluated apoptosis induced by these compounds using flow cytometry on kras and braf mutated cell lines. |
2013-03-19 |
2023-08-12 |
Not clear |
| Toshiyuki Tsunoda, Takeharu Ota, Takahiro Fujimoto, Keiko Doi, Yoko Tanaka, Yasuhiro Yoshida, Masahiro Ogawa, Hiroshi Matsuzaki, Masato Hamabashiri, Darren R Tyson, Masahide Kuroki, Shingo Miyamoto, Senji Shirasaw. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Molecular cancer. vol 11. 2012-12-13. PMID:22830422. |
we previously established a three-dimensional (3-d) colonic crypt model using hke3 cells which are human colorectal cancer (crc) hct116 cells with a disruption in oncogenic kras, and revealed the crucial roles of oncogenic kras both in inhibition of apoptosis and in disruption of cell polarity; however, the molecular mechanism of kras-induced these 3-d specific biological changes remains to be elucidated. |
2012-12-13 |
2023-08-12 |
human |
| Eunju Park, Jinah Park, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Ban. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. International journal of oncology. vol 40. issue 4. 2012-08-31. PMID:22159814. |
the synergistic efficacy study demonstrated that dual pi3k and stat3 blockade showed a synergism in cells harboring mutated kras by inducing apoptosis. |
2012-08-31 |
2023-08-12 |
human |
| Yeon Tae Chung, Kristina A Matkowskyj, Haonan Li, Han Bai, Wanying Zhang, Ming-Sound Tsao, Jie Liao, Guang-Yu Yan. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 25. issue 5. 2012-08-23. PMID:22222635. |
oncogenic function of akr1b10 was examined in pancreatic carcinoma cells in vitro using western blotting and sirna approaches, mainly on cell apoptosis and protein prenylation including kras protein and its downstream signals. |
2012-08-23 |
2023-08-12 |
Not clear |
| Yeon Tae Chung, Kristina A Matkowskyj, Haonan Li, Han Bai, Wanying Zhang, Ming-Sound Tsao, Jie Liao, Guang-Yu Yan. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 25. issue 5. 2012-08-23. PMID:22222635. |
sirna-mediated silencing of akr1b10 expression in pancreatic cancer cells resulted in (1) increased cell apoptosis, (2) increased non-farnesyled hdj2 protein and (3) decreased membrane-bound prenylated kras protein and its downstream signaling molecules including phosphorylated erk and mek and membrane-bound e-cadherin. |
2012-08-23 |
2023-08-12 |
Not clear |
| Neda Mosakhani, Virinder Kaur Sarhadi, Ioana Borze, Marja-Liisa Karjalainen-Lindsberg, Jari Sundström, Raija Ristamäki, Pia Osterlund, Sakari Knuutil. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes, chromosomes & cancer. vol 51. issue 1. 2012-07-20. PMID:21922590. |
we identified some predicted target genes of differentially expressed mirnas between mutated and wild-type kras, such as rsg3 and tob1, which are involved in apoptosis and proliferation. |
2012-07-20 |
2023-08-12 |
Not clear |
| Ninel Azoitei, Christopher M Hoffmann, Jana M Ellegast, Claudia R Ball, Kerstin Obermayer, Ulrike Gößele, Britta Koch, Katrin Faber, Felicitas Genze, Mark Schrader, Hans A Kestler, Hartmut Döhner, Gabriela Chiosis, Hanno Glimm, Stefan Fröhling, Claudia Schol. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. The Journal of experimental medicine. vol 209. issue 4. 2012-06-04. PMID:22451720. |
pharmacologic inhibition of hsp90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of stk33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in kras mutant cells in an stk33-dependent manner. |
2012-06-04 |
2023-08-12 |
human |
| J S Richards, H-Y Fan, Z Liu, M Tsoi, M-N Laguë, A Boyer, D Boerboo. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene. vol 31. issue 12. 2012-05-25. PMID:21860425. |
conversely, expression of oncogenic kras(g12d) dramatically arrests proliferation, differentiation and apoptosis in granulosa cells, and consequently, small abnormal follicle-like structures devoid of oocytes accumulate in the ovary. |
2012-05-25 |
2023-08-12 |
mouse |
| b' Mireia Berdiel-Acer, Monika E Bohem, Adriana L\\xc3\\xb3pez-Doriga, August Vidal, Ramon Salazar, Maria Mart\\xc3\\xadnez-Iniesta, Cristina Santos, Xavier Sanjuan, Alberto Villanueva, David G Mollev\\xc3\\xa. Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia (New York, N.Y.). vol 13. issue 10. 2012-03-16. PMID:22028619.' |
sustained stimulation with caf-lm cm evoked a transient g(2)/m cell cycle arrest accompanied by a reduction of apoptosis, inhibition of proliferation, and decreased viability of sw1116, sw620, sw480, dld1, ht-29, and caco-2 cells and provoked nonapoptotic cell death in those cells carrying kras mutations. |
2012-03-16 |
2023-08-12 |
Not clear |
| Hiromichi Ebi, Ryan B Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P Ryan, Jeffrey A Meyerhardt, Cyril Benes, Jeffrey Settleman, Kwok-Kin Wong, Lewis C Cantley, Jeffrey A Engelma. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of clinical investigation. vol 121. issue 11. 2012-01-03. PMID:21985784. |
here, we have elucidated the molecular regulation of both the pi3k/akt and mek/erk signaling pathways in kras mutant colorectal cancer cells and identified combination therapies that lead to robust cancer cell apoptosis. |
2012-01-03 |
2023-08-12 |
mouse |
| Hiromichi Ebi, Ryan B Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P Ryan, Jeffrey A Meyerhardt, Cyril Benes, Jeffrey Settleman, Kwok-Kin Wong, Lewis C Cantley, Jeffrey A Engelma. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of clinical investigation. vol 121. issue 11. 2012-01-03. PMID:21985784. |
interestingly, combination of rtk and mek inhibitors led to concomitant inhibition of pi3k and mek signaling, marked growth suppression, and robust apoptosis of human kras mutant colorectal cancer cell lines in vitro and upon xenografting in mice. |
2012-01-03 |
2023-08-12 |
mouse |
| Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, Sandrine Faivr. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targeted oncology. vol 6. issue 2. 2011-11-21. PMID:21533544. |
while activation of the phosphatidylinositol 3 kinase (pi3k)/akt/mammalian target of rapamycin (mtor) pathway, overexpression of cyclin d1, and functional apoptosis seem to sensitize tumor cells to rapalogs, bcl2 overexpression or kras mutations are reported to be associated with resistance to mtor inhibitors in several preclinical models. |
2011-11-21 |
2023-08-12 |
Not clear |
| Amandine Hurbin, Marie Wislez, Benoît Busser, Martine Antoine, Corine Tenaud, Nathalie Rabbe, Sandrine Dufort, Florence de Fraipont, Denis Moro-Sibilot, Jacques Cadranel, Jean-Luc Coll, Elisabeth Brambill. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of pathology. vol 225. issue 1. 2011-10-24. PMID:21598249. |
anti-amphiregulin sirnas and anti-igf1r treatments sensitized the h358 cells to gefitinib-induced apoptosis with additive effects, suggesting that these treatments could overcome the resistance of mucinous tumours to egfr-tkis, including those with kras mutation. |
2011-10-24 |
2023-08-12 |
Not clear |
| Feijun Luo, George Poulogiannis, Hongtao Ye, Rifat Hamoudi, Mark J Arend. Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncology reports. vol 26. issue 1. 2011-10-21. PMID:21573497. |
k-ras (kras) is mutated in 40-50% of human colorectal adenomas and carcinomas and plays key roles in cell proliferation, apoptosis, motility and differentiation, but its functional contribution to intestinal tumourigenesis in vivo remains incompletely understood. |
2011-10-21 |
2023-08-12 |
mouse |
| Shaoyi Huang, Xiaoyang Ren, Lai Wang, Ling Zhang, Xiangwei W. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Cancer prevention research (Philadelphia, Pa.). vol 4. issue 5. 2011-09-27. PMID:21543344. |
in this study, we developed a new approach for the chemoprevention of nsclc involving specific targeting of apoptosis in mutant kras cells. |
2011-09-27 |
2023-08-12 |
Not clear |
| Shaoyi Huang, Xiaoyang Ren, Lai Wang, Ling Zhang, Xiangwei W. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Cancer prevention research (Philadelphia, Pa.). vol 4. issue 5. 2011-09-27. PMID:21543344. |
therefore, the combination of trail and a small molecule mimic of smac induced apoptosis specifically in mutant kras cells without harming normal cells. |
2011-09-27 |
2023-08-12 |
Not clear |
| Thaddeus D Allen, Chang Qi Zhu, Kirk D Jones, Naoki Yanagawa, Ming-Sound Tsao, J Michael Bisho. Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer research. vol 71. issue 6. 2011-07-25. PMID:21406400. |
tumorigenesis was assisted by either spontaneous mutations in kras or experimental introduction of activated ras, but investigations revealed that additional events were required to circumvent apoptosis, one of the most significant negative functions exerted by myc. |
2011-07-25 |
2023-08-12 |
mouse |
| Julie E Niemela, Lianghao Lu, Thomas A Fleisher, Joie Davis, Iusta Caminha, Marc Natter, Laurel A Beer, Kennichi C Dowdell, Stefania Pittaluga, Mark Raffeld, V Koneti Rao, João B Oliveir. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. vol 117. issue 10. 2011-05-16. PMID:21079152. |
the activating kras mutation impaired cytokine withdrawal-induced t-cell apoptosis through the suppression of the proapoptotic protein bcl-2 interacting mediator of cell death and facilitated proliferation through p27(kip1) down-regulation. |
2011-05-16 |
2023-08-12 |
human |
| E F Dunn, M Iida, R A Myers, D A Campbell, K A Hintz, E A Armstrong, C Li, D L Wheele. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. vol 30. issue 5. 2011-04-22. PMID:20956938. |
combinatorial treatment of kras mutant xenografts resulted in decreased cell proliferation, as measured by ki67, and higher rates of apoptosis, as measured by tunel (terminal deoxynucleotidyl transferase-mediated dutp nick end labeling). |
2011-04-22 |
2023-08-12 |
human |
| Marcus Fischer, Wan-Ching Yen, Ann M Kapoun, Min Wang, Gilbert O'Young, John Lewicki, Austin Gurney, Timothy Hoe. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer research. vol 71. issue 5. 2011-04-21. PMID:21193546. |
further analysis of mutant kras tumors indicated that the anti-dll4/irinotecan combination produced a significant decrease in colon cancer stem cell frequency while promoting apoptosis in tumor cells. |
2011-04-21 |
2023-08-12 |
Not clear |